Dr. Tijana Milinic and Lia Barros, DNP, from the University of Washington take a deep dive into the world of pulmonary arterial hypertension (PAH) clinical trials and discuss why diversity and inclusion matter. They explore the hidden biases in medical research and the real-world consequences of exclusion.

Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials [https://www.phaware.global/clinicaltrials]. Engage for a cure: www.phaware.global/donate [https://www.phaware.global/donate] #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com [https://www.phawarepodcast.com]. @uwepidemiology  [https://twitter.com/uwepidemiology/] #phawareMD

Episode 529 - Lia Barros, DNP and Tijana Milinic, MD

Dr. Lana Melendres-Groves dives into her research on racial and ethnic disparities in PAH treatment. From differences in medication access to the role of social determinants of health, she explores how systemic barriers impact care and what steps can be taken to ensure equity and inclusivity in PAH management.

Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials [https://www.phaware.global/clinicaltrials]. Engage for a cure: www.phaware.global/donate [https://www.phaware.global/donate] #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com [https://www.phawarepodcast.com]. @UNMHSC [https://x.com/unmhsc] #phawareMD

Episode 528 - Lana Melendres-Groves, MD

Dr. Roham Zamanian, discusses the concept of "disease modification" in the treatment of pulmonary hypertension. He describes how this idea emerged from discussions with colleagues about the future of pulmonary hypertension therapies, and the potential for treatments to impact the underlying disease process beyond just reducing pulmonary artery pressures.

This Special Edition Episode Sponsored by: Johnson & Johnson [https://innovativemedicine.jnj.com/our-innovation/focus-areas/cardiopulmonary/pulmonary]

Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials [http://www.phaware.global/clinicaltrials]. Follow us on social @phaware Engage for a cure: www.phaware.global/donate [https://www.phaware.global/donate] #phaware Share your story: info@phaware.com #phawareMD @PHatStanford [https://x.com/PHatStanford] @docroham [https://x.com/docroham] @JNJInnovMed [https://x.com/JNJInnovMed]

   

Episode 527 - Roham Zamanian, MD, FCCP

Hall Skaara, representing PHA Europe, brought the patient perspective [https://publications.ersnet.org/content/erj/early/2024/06/13/1399300301129-2024?fbclid=IwY2xjawE_KtNleHRuA2FlbQIxMAABHTdIu7esYdmEbhnq4MNOvKk3HJBy8gi9zKKT1guNdBoKng7zBoESSuCwAA_aem_gT3lP1CyrTWco4smoUlauw] to the forefront at the World Symposium on Pulmonary Hypertension, joining other members of Task Force 1. PHA Europe was well-represented with delegates including Eva Otter, Monika Tschida, Natalia Maeva, Tadeja Ravnik, and Nina Kobler. This prestigious event gathered over 1,500 of the brightest minds in the field of pulmonary hypertension, offering a unique opportunity for patients and professionals to collaborate and share insights, as well as for patient associations to network.

This Special Edition Episode Sponsored by: Johnson & Johnson [https://innovativemedicine.jnj.com/our-innovation/focus-areas/cardiopulmonary/pulmonary]

Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials [http://www.phaware.global/clinicaltrials]. Follow us on social @phaware Engage for a cure: www.phaware.global/donate [https://www.phaware.global/donate] #phaware Share your story: info@phaware.com @EuropePHA [https://x.com/EuropePHA] @Hall_Skaara [https://x.com/Hall_Skaara] @JNJInnovMed [https://x.com/JNJInnovMed]

Episode 526 - Hall Skaara

Why Pulmonary Hypertension Isn’t Just a Lung ProblemCardiologist Dr. Lisa Mielniczuk from the Mayo Clinic pulls back the curtain on one of the most common — yet misunderstood — forms of pulmonary hypertension: the kind caused by left heart disease. In this episode, she explains why it’s time we stop thinking of PH as a rare condition. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials [http://www.phaware.global/clinicaltrials]. Follow us on social @phaware Engage for a cure: www.phaware.global/donate [https://www.phaware.global/donate] #phaware Share your story: info@phaware.com @phacanada  [https://twitter.com/PHACanada] #phawareMD @mayoclinic [https://x.com/MayoClinic] @teamphhope [https://x.com/teamphhope]

Episode 525 - Lisa Mielniczuk, MD

Beyond the Clinical Trial: What Real-World Data Means for You Think only people in clinical trials help advance medicine? Think again. Dr. Jason Weatherald explains how your everyday clinic visits — from walk tests to how you feel — can help shape the future of pulmonary hypertension treatment. Learn what "real-world evidence" is and why your story matters more than you think. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials [http://www.phaware.global/clinicaltrials]. Follow us on social @phaware Engage for a cure: www.phaware.global/donate [https://www.phaware.global/donate] #phaware Share your story: info@phaware.com @phacanada  [https://twitter.com/PHACanada] #phawareMD @teamphhope [https://x.com/teamphhope]  @AlbertaPHdoc [https://x.com/albertaphdoc] @UAlberta [https://x.com/UAlberta]

Episode 524 - Dr. Jason Weatherald

Dr. Rodolfo Estrada, is a seasoned pulmonologists currently at UT Health San Antonio with significant experience in the management of patients with different forms of pulmonary hypertension. In this episode, Dr. Estrada will discuss the technology and clinical development behind YUTREPIA™ (treprostinil) inhalation powder and why it might be a good option for some PAH and PH-ILD patients. This Special Edition episode is sponsored by Liquidia [https://liquidia.com/]. Please see the Important Safety Information following this podcast. The Prescribing Information and Instructions for Use for YUTREPIA (treprostinil) inhalation powder are available at YUTREPIA.com. [https://www.yutrepia.com/] 

YUTREPIA is approved for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve the ability to exercise. Please see the Important Safety Information in the show notes. The Prescribing Information and Instructions for Use for YUTREPIA are available at YUTREPIA.com. [https://www.yutrepia.com/] Learn more about the INSPIRE study. [https://onlinelibrary.wiley.com/doi/10.1002/pul2.12119]

Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials [https://www.phaware.global/clinicaltrials]. Engage for a cure: www.phaware.global/donate [https://www.phaware.global/donate] #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com [https://www.phawarepodcast.com/]. #phawareMD #PHILD @Liquidia_Corp [https://x.com/Liquidia_Corp] @REstradaMD [https://x.com/REstradaMD] @UTHealthSA [https://x.com/UTHealthSA]

IMPORTANT SAFETY INFORMATION Before you take YUTREPIA, tell your healthcare provider about all of your medical conditions, including if you:

 * Have low blood pressure
 * Have or have had bleeding problems
 * Have asthma or chronic obstructive pulmonary disease (COPD)
 * Are pregnant or plan to become pregnant. It is not known if this product will harm your unborn baby
 * Are breastfeeding or plan to breastfeed. It is not known if this product passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. YUTREPIA and other medicines may affect each other.

Especially tell your healthcare provider if you take:

 * Medicines used to treat high blood pressure or heart disease
 * Medicines that decrease blood clotting (anticoagulants)
 * Water pills (diuretics)
 * Gemfibrozil (Lopid®) or rifampin (Rimactane®, Rifadin®, Rifamate®, Rifater®)

What are the possible side effects of YUTREPIA?

This product can cause serious side effects,

Episode 523 - Rodolfo Estrada, MD

Decoding Pulmonary Hypertension: Echo and Cath Insights for Pulmonologists. Dr. Marc Simon shares his expertise on diagnosing pulmonary hypertension, emphasizing echocardiographic markers, right heart catheterization pitfalls, and risk stratification with the H2FPEF score. His insights help clinicians refine their diagnostic approach for better patient outcomes.

This Special Edition episode is sponsored by Liquidia [https://liquidia.com/]. View PDF Slides here [https://content.libsyn.com/p/1/5/c/15cb97d4bc596a58/Simon_EchoRHC_talk_for_Pulm_CTS2025.pdf?c_id=186607620&cs_id=186607620&response-content-type=application%2Fpdf&Expires=1748276267&Signature=eNe-It0tjIJg9Q7SDwmoPi574MW0JVE23MZzqozJzJWoF2DbyyxAisgePCqclP7vaVEFUe92GuF6V8geCH2EbU7IhGVgHFEApYNcJdnkgtGOpKzrEIP4hLP%7E4gAv%7E52gYCPIsB7yexAlXleP2wf4IlRA3rbdNLKn4JdMqYo0mFGkUhQANJgF4JepZQYpqZsQ%7E8BDn%7Ef9pJvzOLp2sLey8HGvajy1VerfQXU99o6hUSXc61ZIhBpN05w2TsoOor3w4amEljNrfrI8xGKEcZfNSf9ttusknYy3CyufeY-G3jfTnB8uKDGk3K2qmZigvQbfLzQLlOUBiBx3mZ%7EKJwd21A__&Key-Pair-Id=K1YS7LZGUP96OI]. 

Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials [https://www.phaware.global/clinicaltrials]. Engage for a cure: www.phaware.global/donate [https://www.phaware.global/donate] #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com [https://www.phawarepodcast.com]. #phawareMD #PHILD @Liquidia_Corp [https://x.com/Liquidia_Corp] @UCSFCardiology [https://x.com/UCSFCardiology] @MarcSimonMD [https://x.com/MarcSimonMD] @CalThoracic [https://x.com/CalThoracic]

Episode 522 - Marc Simon, MD

Dr. Jean Elwing, a leading expert in pulmonary hypertension, discusses groundbreaking advancements in treating pulmonary hypertension associated with interstitial lung disease (PH-ILD). For years, patients with this condition had limited treatment options beyond oxygen therapy and symptom management. However, recent studies have introduced new hope, showing improved patient outcomes and quality of life. Dr. Elwing emphasizes the importance of early diagnosis, ongoing research, and clinical trial participation in pushing the field forward.

This Special Edition episode is sponsored by Gossamer Bio [https://www.gossamerbio.com/] and Pulmovant [https://www.pulmovant.com/].

Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials [https://www.phaware.global/clinicaltrials]. Engage for a cure: www.phaware.global/donate [https://www.phaware.global/donate] #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com [https://www.phawarepodcast.com]. #phawareMD #PHILD  @uc_health [https://x.com/uc_health] @ElwingJean [https://x.com/ElwingJean] @GossamerBio [https://x.com/GossamerBio] #Pulmovant [https://x.com/hashtag/Pulmovant?src=hashtag_click] @accpchest  [https://x.com/accpchest] #PHOCUSstudy #PROSERAstudy

Episode 521 - Jean M. Elwing, MD

Seth Hall, MBA, RRT, takes listeners on a journey through the past, present, and future of inhaled therapies. Discover how these treatments have evolved, the life-changing benefits they offer, and the revolutionary technologies that could redefine outcomes for PAH and PH-ILD patients. This Special Edition episode is sponsored by Liquidia [https://liquidia.com/].

Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials [https://www.phaware.global/clinicaltrials]. Engage for a cure: www.phaware.global/donate [https://www.phaware.global/donate] #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com [https://www.phawarepodcast.com]. #phawareMD #PHILD @Liquidia_Corp [https://x.com/Liquidia_Corp] #PRINTTechnology 

Episode 520 - Seth Hall, MBA, RRT

I'm Aware That I'm Rare: the phaware® podcast is devoted to raising global pulmonary hypertension awareness with dynamic stories from PH patients, caregivers and medical professionals from around the world. Through this series of impactful, insightful and, most importantly, hopeful stories from members of the global pulmonary hypertension community, we hope to further the global #phaware conversation as well as to capture, engage and enable misdiagnosed and undiagnosed PH patients because early diagnosis and treatment can mean the difference between life and death. Topics range from the importance of early diagnosis and global PH awareness, to the impact of clinical trials to how patient support and advocacy are paramount to battling this disease. Learn more about PH at www.phaware.global

Steve Van Wormer

Shows